Stockscreener 앱 받기
31.84
0.06%
0.02
시간 외 거래:
31.84
전일 마감가:
$31.82
열려 있는:
$31.98
하루 거래량:
788.06K
Relative Volume:
0.73
시가총액:
$1.89B
수익:
$66.05M
순이익/손실:
$-422.60M
주가수익비율:
-4.3911
EPS:
-7.251
순현금흐름:
$-384.73M
1주 성능:
+13.15%
1개월 성능:
+13.03%
6개월 성능:
+22.04%
1년 성능:
-10.94%
1일 변동 폭
$31.30
$32.52
1주일 범위
$27.70
$32.52
52주 변동 폭
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
명칭
Agios Pharmaceuticals Inc
전화
617-649-8600
주소
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
31.84 | 1.89B | 66.05M | -422.60M | -384.73M | -7.251 |
VRTX
Vertex Pharmaceuticals Inc
|
453.17 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.73 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
878.49 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
281.90 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
156.58 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-20 | 재확인 | H.C. Wainwright | Buy |
| 2025-11-24 | 개시 | Truist | Buy |
| 2025-11-20 | 업그레이드 | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | 개시 | H.C. Wainwright | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-09-27 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-02-03 | 개시 | Piper Sandler | Overweight |
| 2022-11-17 | 업그레이드 | Goldman | Sell → Neutral |
| 2022-07-27 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | 개시 | BofA Securities | Buy |
| 2021-07-30 | 다운그레이드 | Goldman | Neutral → Sell |
| 2021-07-01 | 개시 | Raymond James | Mkt Perform |
| 2021-06-10 | 개시 | H.C. Wainwright | Buy |
| 2021-03-01 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2021-03-01 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2020-03-04 | 개시 | Barclays | Equal Weight |
| 2019-11-26 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-09-23 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-02-15 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | 개시 | Leerink Partners | Mkt Perform |
| 2018-05-23 | 개시 | Citigroup | Buy |
| 2018-04-11 | 재확인 | Credit Suisse | Outperform |
| 2018-02-15 | 재확인 | Needham | Buy |
| 2018-02-15 | 재확인 | SunTrust | Buy |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-08-10 | 재확인 | Needham | Buy |
| 2017-08-08 | 재확인 | SunTrust | Buy |
| 2017-08-02 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | 다운그레이드 | Janney | Buy → Neutral |
| 2017-01-17 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2016-10-24 | 개시 | Needham | Buy |
| 2016-06-13 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2016-05-18 | 재확인 | SunTrust | Buy |
모두보기
Agios Pharmaceuticals Inc 주식(AGIO)의 최신 뉴스
Agios Pharmaceuticals, Inc. (AGIO) Discusses New Data and Strategic Expansion in Rare Hematology at EHA Investor EventSlideshow (NASDAQ:AGIO) 2026-06-15 - Seeking Alpha
Agios to discontinue candidate for myelodysplastic syndromes - MSN
Agios Pharmaceuticals (AGIO) Reports Promising Results from Phas - GuruFocus
Agios Pharmaceuticals touts mitapivat gains despite sickle cell pain miss - MSN
Agios Pharmaceuticals Touts Mitapivat Gains Despite Sickle Cell Pain Miss - Yahoo Finance
AGIO: Mitapivat shows durable efficacy in rare hematology, supporting growth and pipeline expansion - TradingView
Technical Reactions to AGIO Trends in Macro Strategies - Stock Traders Daily
Agios presents detailed mitapivat trial results for sickle cell - Investing.com UK
Agios presents detailed mitapivat trial results for sickle cell By Investing.com - Investing.com Australia
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease - The Manila Times
Agios Pharmaceuticals Reports Positive Phase 3 Results for Mitapivat in Sickle Cell Disease, Highlighting Hemoglobin Response and Reduced Transfusion Burden - Quiver Quantitative
Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong ... - Caledonian Record
Sickle cell patients needed fewer transfusions with Agios pill in Phase 3 - Stock Titan
Agios Pharmaceuticals (NASDAQ:AGIO) Given New $31.00 Price Target at JPMorgan Chase & Co. - MarketBeat
J.P. Morgan Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Maintains Target Price $31 - Moomoo
GW&K Investment Management LLC Purchases 354,359 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
J.P. Morgan Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Announces Target Price $31 - Moomoo
Capital International Investors Buys New Position in Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
Agios Pharmaceuticals, Inc. $AGIO Shares Bought by BNP Paribas Financial Markets - MarketBeat
‘Disciplined’ $665M deal moves Oscotec’s cevidoplenib to Agios - BioWorld News
Eyes on Asia: Olix, Agios, Eli Lilly - BioXconomy
Analysts’ Top Healthcare Picks: McKesson (MCK), Agios Pharma (AGIO) - The Globe and Mail
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $40 - Moomoo
Alpha Thalassemia Market Emerging as a High-Growth Healthcare Investment Space Through 2036 – DelveInsight | Forma Therapeutics, Genmedicn Biopharma, Bristol-Myers Squibb, Agios Pharma - Barchart.com
Erste Asset Management GmbH Acquires 40,000 Shares of Agios Pharmaceuticals, Inc. $AGIO - MarketBeat
The week in pharma: action, reaction and insight – week to June 5, 2026 - The Pharma Letter
Why Agios Pharmaceuticals (AGIO) Is Down 5.4% After Overhauling Its Hematology PortfolioAnd What's Next - Sahm
Agios Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Q2 EPS Estimate for Agios Pharmaceuticals Reduced by Analyst - MarketBeat
AGIO secures global rights to late-stage rare blood disorder candidate - MSN
How The Tebapivat Setback Is Reframing The Story For Agios Pharmaceuticals (AGIO) - Yahoo Finance
HC Wainwright Issues Optimistic Estimate for AGIO Earnings - MarketBeat
AGIO Secures Global Rights to Late-Stage Rare Blood Disorder Candidate - The Globe and Mail
Trading the Move, Not the Narrative: (AGIO) Edition - Stock Traders Daily
Analysts Are Bullish on Top Healthcare Stocks: Agios Pharma (AGIO), Cogent Biosciences (COGT) - The Globe and Mail
Agios inks global licensing agreement with Oscotec - The Pharma Letter
Oscotec Signs Up to $665 Million Licensing Deal with Agios Pharmaceuticals for Autoimmune Drug Candidate Cevidoplenib - 알파경제
Agios Halts Tebapivat Trials As Sickle Cell Focus Shapes Valuation - Sahm
Agios Pharmaceuticals, Inc. (AGIO) Discusses Global License Agreement for Cevidoplenib and Strategic Expansion in Rare HematologySlideshow (NASDAQ:AGIO) 2026-06-01 - Seeking Alpha
Agios Pharmaceuticals licenses global rights to Oscotec's SYK inhibitor cevidoplenib - Yahoo Finance
Agios scraps blood cancer drug program after study miss - AOL.com
AGIO Halts Tebapivat Development in Myelodysplastic Syndromes - The Globe and Mail
AGIO: Cevidoplenib licensed for ITP, with strong phase II data and phase III planned for 2028 - TradingView
Agios licenses oral SYK inhibitor for rare blood disorder By Investing.com - Investing.com South Africa
Agios Pharmaceuticals (AGIO) Forms Licensing Deal for Cevidoplen - GuruFocus
AGIO: Exclusive global license for cevidoplenib expands rare hematology pipeline and targets ITP - TradingView
Agios licenses oral SYK inhibitor for rare blood disorder - Investing.com UK
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize Next-Generation SYK Inhibitor Cevidoplenib - The Manila Times
Agios Pharmaceuticals Secures Exclusive Global Rights to Next-Generation SYK Inhibitor Cevidoplenib for Immune Thrombocytopenia Treatment - Quiver Quantitative
Agios Enters Exclusive Global License Agreement with Oscotec to Develop and Commercialize ... - Caledonian Record
Rare blood disorder drug deal gives Agios shot at $1B U.S. sales - Stock Titan
Agios Pharmaceuticals Inc (AGIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Agios Pharmaceuticals Inc 주식 (AGIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Burns James William | Chief Legal Officer |
Apr 02 '26 |
Sale |
34.71 |
3,280 |
113,849 |
49,306 |
| Gheuens Sarah | Chief Medical Officer |
Apr 02 '26 |
Option Exercise |
0.00 |
8,500 |
0 |
83,217 |
| Gheuens Sarah | Chief Medical Officer |
Apr 02 '26 |
Sale |
34.71 |
2,940 |
102,047 |
80,277 |
| Jones Cecilia | Chief Financial Officer |
Apr 02 '26 |
Option Exercise |
0.00 |
8,500 |
0 |
58,139 |
| Jones Cecilia | Chief Financial Officer |
Apr 02 '26 |
Sale |
34.71 |
3,141 |
109,024 |
54,998 |
| Milanova Tsveta | Chief Commercial Officer |
Apr 02 '26 |
Option Exercise |
0.00 |
8,500 |
0 |
50,091 |
| Milanova Tsveta | Chief Commercial Officer |
Apr 02 '26 |
Sale |
34.71 |
3,262 |
113,224 |
46,829 |
| Viswanadhan Krishnan | Chief Corp Dev & Strategy |
Apr 02 '26 |
Option Exercise |
0.00 |
8,100 |
0 |
13,241 |
| Viswanadhan Krishnan | Chief Corp Dev & Strategy |
Apr 02 '26 |
Sale |
34.71 |
2,959 |
102,707 |
10,282 |
| Goff Brian | Chief Executive Officer |
Apr 02 '26 |
Option Exercise |
0.00 |
39,028 |
0 |
191,104 |
1.27%
1.43%
자본화:
|
볼륨(24시간):